
    
      LCH115397 was a phase 2a, open label, multicenter study testing 125 mg (starting dose) daily
      oral GSK2110183 in adult and adolescent patients with Langerhans Cell Histiocytosis. The
      primary objectives of the study were efficacy (at 3 and 6 months) and safety. For the purpose
      of efficacy analysis, patients were stratified into two groups: treatment-na√Øve (Stratum 1)
      and refractory or reactivation disease (Stratum 2). Adolescent participation was limited to
      patients with refractory or reactivation disease (Stratum 2).
    
  